Definium Therapeutics Inc (DFTX)

Definium Therapeutics (NASDAQ:DFTX) Chief Financial Officer Brandi Roberts said the company is preparing for several key clinical and regulatory milestones for DT-120, including anticipated Phase III data...

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological...

The primary endpoint will measure the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 between DT120 Orally Disintegrating Tablet (ODT) 100 µg and placebo...

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...

Definium Therapeutics (NASDAQ:DFTX) reported first-quarter 2026 financial results and outlined a series of near-term clinical milestones for its lead candidate, DT120 ODT, during a conference call held...

Three Phase 3 topline data readouts for DT120 ODT expected in the coming months DT120 ODT program expanded into PTSD with Phase 3 Haven study expected to initiate in...

Barchart Research What to Expect from DFTX Earnings DFTX Generated May 6, 2026 Current Price $23.42 EPS Estimate $$-0.47 Consensus Rating Strong Buy Average Move 4.80% Definium Therapeutics Prepares to...

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological...

Psychedelic drugs could get a big boost thanks to a recent executive order, and these firms all have promising candidates in line.

MDD: Emerge topline data readout on track for late 2Q 2026; Ascend sites activated with first patient dosing anticipated in 2Q 2026 GAD: Voyage enrollment complete with...